His research has focused on the immunopathogenesis and immunotherapy of autoimmune Type 1 diabetes (T1D). In particular, his studies on T cells, cytokines and chemokines have provided strong support for the notion that immune dysregulation is a principal factor that controls susceptibility to T1D in animal models of the disease, and were the first to show that IL-4 and iNKT cells can induce protection from T1D. He has published more than 170 papers, was the Founding Scientist and Vice-President Research at Diabetogen Biosciences Inc., has served on editorial boards of several major immunology journals, and has been a member of evaluation committees of numerous granting agencies, including the Juvenile Diabetes Research Foundation, National Institutes of Health, Arthritis Society of Canada and National Cancer Institute of Canada. Immunology Department at the Holland Laboratory, the R&D center of the American Red Cross. He has served on the editorial boards of major immunological journals and as a member of study sections of the National Institutes of Health, the National Multiple Sclerosis Society and the American Cancer Society. Over the course of his career, Dr Scott has focused on mechanisms of immune tolerance, and more recently on a platform for gene therapy for tolerance in autoimmune diseases and hemophilia. He has contributed to over 180 research papers on a variety of subjects, including immunologic tolerance, B-and T-cell signaling, gene therapy, and cell cycle control Autoimmune diseases present a significant health burden on our society, as they affect as many as 6% of the population and are the third largest disease burden after heart disease and cancer. Autoimmune pathology arises from the damaging reactions of self-reactive T cells to autoantigens and/or B-cell derived autoantibodies, and can be triggered by genetic and environmental factors. Among the major autoimmune diseases, rheumatoid arthritis (RA), Type 1 diabetes (T1D), multiple sclerosis (MS), systemic lupus erythematosus (SLE), inflammatory bowel disease (IBD) and others are polygenic in nature. Hence, these diseases are under the control of several genes, including major histocompatibility complex (MHC) linked genes that govern the specificity of an adaptive immune response, as well as numerous non-MHC linked genes including those mapping within cytokine loci.
Autoreactive lymphocytes with pathogenic potential can be found in the periphery of normal animals and individuals, and their activity of these lymphocytes might be regulated in the periphery by tolerance mechanisms that include clonal ignorance, deletion, anergy, immune deviation and suppression. The latter tolerance mechanisms, in particular, are mediated by interactions between T cells, B cells and dendritic cells (DC). Thus, the immune response of a genetically susceptible individual to an environmental pathogen when accompanied by defects in immunoregulatory mechanisms that alter T-B-DC interactions can lead us to a state of 'immune dysregulation', and the ensuing development of an autoimmune disease. For example, during a microbial infection, a failure in one or more of these immunoregulatory mechanisms can lead us to a breakdown of self-tolerance, immune responsiveness to cross-reactive autoantigens (socalled mimicry) and culminate in organ/tissue damage and disease. Currently, much attention is being devoted to the role of defects in various subsets of regulatory T cells (CD4+CD25+, NKT, Tr1 cells, among others) in the immunopathogenesis of several autoimmune diseases.
Presently, there is no known cure of many autoimmune diseases, and treatments are restricted to toxic, long-term immunosuppressive regimes, cell replacement therapy and in intractable cases, transplantation of autologous or heterologous hematopoietic stem cells. Thus, development of therapies that target defective genes, proteins and cells of the immune system are being pursued in experimental animal models of autoimmune disease with the aim to establish proof of principle in subsequent therapeutic clinical trials. Efforts are being made to block/reverse processes that lead us to loss of tolerance, including the use of biologics that eliminate autoreactive lymphocytes or restore tolerance.
The reviews in this issue discuss the underlying mechanisms and approaches that mediate the pathogenesis and attempts to achieve gene and/or cell replacement therapy of several autoimmune diseases, including T1D, RA, MS, SLE, IBD, uveitis, myocarditis, cancer, bone marrow transplantation, acute respiratory distress syndrome and hematologic disorders (such as ITP).
Yu and Eisenbarth review evidence that immune-mediated T1D is usually preceded by a long prodrome characterized by the presence of autoantibodies to several islet autoantigens. They consider a model in which the natural history of T1D consists of several stages, progressing from genetic susceptibility to islet beta-cell destruction and overt diabetes. Although prediction is possible in humans, and multiple therapies prevent T1D in animal models, improved therapies and monitoring of T-cell autoimmunity are invoked to achieve safe and effective prevention of immune-mediated beta cell destruction in humans.
RA is one of the most common autoimmune diseases, targeting the joints and bone. In their article, Deng and Lenardo focus on the roles played by tumor necrosis factor alpha (TNFa) as well as members of the TNF-receptor family, like RANK and RANK ligand as crucial factors in bone destruction, and as potential therapeutic targets in RA. Joosten and colleagues review the role of the pro-inflammatory cytokine interleukin (IL-1) in inflammatory and autoimmune diseases. Emphasis is given to the capacity of IL-1 to trigger acute and chronic inflammation in a chronic joint disease such as RA, and to the ability of IL-1 blockade to inhibit the progression of acute and chronic inflammation.
Podejil and Miller provide an overview of the genetic basis for MS and suggest that the influence of environmental factors with the interaction of MHC antigens with variants of costimulatory molecules, like CTLA-4, might be crucially involved in the activation of CNS-specific T cells. The latter molecule can provide clinical targets for drug development.
Katsiari and Tsokos review the etiology of SLE, as a broad syndrome with multiple target antigens. The roles of complement family members, aberrant T cell signaling and cytokine dysfunction in SLE must be considered to provide rationale drug design. Coupled with contemporary approaches in genomics and proteomics, these studies could lead us to the development of broad as well as patient-specific therapies.
Invariant natural killer T (iNKT) cells, which recognize glycolipids presented by CD1d, have recently been implicated in the regulation of many autoimmune diseases. Molano and Porcelli review here the immunoregulatory mechanisms involved in iNKT-mediated protection from T1D, RA, MS and SLE. They discuss that targeting iNKT cells with specific glycolipid activators can prove therapeutic for these and other autoimmune diseases.
Uveoretinitis of autoimmune etiology is seen in multiple disease settings, including Birdshot Retinochoroidopathy, Behcet's disease and Sarcoidosis. In her review, Caspi discusses the genetic and physiologic basis of uveitis, and how animal models for experimental uveitis provide insight into potential therapies targeting retinal-specific T cells.
Drug Discovery
One of the major causes of heart failure is myocarditis or its sequelae. Rose and his colleagues discuss this prevalent disease and models implicating a clear role for antigenic mimicry with coxsackie viruses. Their animal model also demonstrates the delicate balance between TH1 and TH2 cytokines that does not fit the paradigm for autoimmune diseases, namely the roles played by IL-13 and IFNg.
Considerable emphasis has been devoted to the development of dendritic cell (DC) based vaccine strategies to treat cancer patients to induce antitumor immunity and tumor regression. Despite dramatic tumor responses in some patients, the majority did not respond. Allison and Engelman discuss some of the limitations encountered and their recent encouraging experience in overcoming these problems in tumor bearing animals treated with a DC activator (Flt3L + CpG) in combination with tumor antigens, or direct tumoral injection of a DC-attracting chemokine (CCL20) plus a DC activator.
Chan, Alderucchio and colleagues discuss the potential of autologous bone marrow transplantation combined with the transduction of known target genes as a curative therapy in animal models of gastritis and T1D. The use of genetically modified hematopoietic stem cells can act as a 'Trojan Horse' to re-educate the immune system and provide a potential cure without the risk of relapse.
Imai, Kuba and Penninger discuss the evidence that points to the crucial importance of the renin-angiotensin system (RAS) in the pathogenesis of the acute respiratory distress syndrome (ARDS) and acute lung injury. They review their studies on the recent identification of angiotensin-converting enzyme-2 (ACE2) as a receptor for the SARS coronavirus (SARS-CoV), and discuss the possibility that modulation of ACE2 might represent a novel therapeutic treatment of ARDS.
Autoimmune hematologic disorders affecting platelets and red blood cells are mediated by antibodies, but are highly Tcell dependent in their formation. Semple and Freedman discuss the cellular basis of autoimmune thrombocytopenic purpura (platelets) and autoimmune hemolytic anemia (red cells), including the role of infection, drug-induced modified epitopes and genetics. Although great progress has been made over the last halfcentury or so in combating infectious diseases, they continue to exact a staggering toll on the global population. For many diseases, such as tuberculosis and HIV, it is increasingly evident that marked disparities in socioeconomic conditions around the world have created vastly different scenarios for the same infections. For example, in most industrialized countries control of tuberculosis has been achieved through coordination of public health efforts and the adequate provision of chemotherapy. Likewise, the accelerated development of an expanding arsenal of highly effective antiretroviral agents and surrogate laboratory markers has arrested the HIV epidemic and enabled treatment of HIV infection as a stable chronic disease in the most highly developed medical delivery systems. But the picture is different in developing countries where the two synergistic epidemics rage on. Control of tuberculosis and HIV in these areas will surely require unprecedented efforts to coordinate public health measures and provide appropriate treatment. But the development of novel therapeutic and prophylactic agents with exceptional potency, efficacy or convenience could become 'great equalizers' that might some day enable global containment and elimination. This issue of Drug Discovery Today: Disease Mechanisms contains articles describing innovative research in these fields that illustrate the interdependence of research efforts to understand basic pathogenic mechanisms and efforts to develop new therapeutic agents. Boshoff and Barry reveal the dynamic nature of the cell wall of nonreplicating Mycobacterium tuberculosis as a source of new drug targets, while Roberts and Deretic probe interaction of the organism with the host phagolysosomal apparatus for clues to new therapeutic interventions. Marchand et al. skillfully review the essential role of the HIV integrase, a target for a new class of potent antiretroviral agents. Two other reviews address another infectious scourge of the developing world, cholera. Van Dellen and Watnick describe exciting new developments in the understanding of bacterial surface adhesion and biofilm formation that might uncover new patient-or population-centered approaches to prevention and treatment. In elucidating the mechanisms of bacterial toxin entry in host cells, Murphy and Harrison attack the fundamental virulence factors of Vibrio cholerae as well as Corynebacterium diphtheriae and open new avenues for antitoxin development. Finally, meningococcal disease causes disproportionate morbidity and mortality in the developing world, but remains a much-feared disease in developed countries as well, where the burden of disease caused by serotype B Neisseria meningitidis remains unaddressed by the recent development of a new conjugated vaccine. In reviewing the current state of knowledge regarding the pathogenesis of meningococcal infection, Bagnoli and Rappuoli describe hopeful new strategies for creating more broadly effective vaccines.
Other problematic infections are consequences medical progress and/or inappropriate use of existing antimicrobials; and pose health-threats in developed as well as developing countries. One pertinent example is the increasing emergence of drug-resistant organisms due to the tremendous antibiotic pressure exerted in the modern practice of medicine. Comprehensive approaches to this problem require more than just better understanding of the pathogenesis of the infection, but also intimate knowledge of the microbial interactions with and adaptations to existing drugs. Freire presents a thermodynamic approach to the inhibition of the HIV protease as a means of identifying the most potent inhibitors capable of overcoming recognized viral resistance mechanisms. Sakoulas thoughtfully describes the emergence of drug resistance in Staphylococcus aureus and recent investigation of the agr locus and its association with glycopeptide resistance in this consummate pathogen. A second consequence of medical progress is the rise of opportunistic infections due to iatrogenic suppression of the immune system. The introduction of tumor necrosis factor-alpha (TNFa) antagonists as a treatment modality for an ever-expanding list of diseases has exposed the crucial role TNFa plays in the containment of specific infections. As described by Deepe and Wallis, fuller appreciation of the infectious disease risks conferred by specific antagonists might shed new light on the interaction between host and microbe and promote the development of next-generation agents with higher selectivity.
The hubris ushered in by the discovery of antimicrobial agents more than a half-century ago has been supplanted by the sobering recognition that infectious diseases are wily, highly adaptable adversaries. As a consequence, drug discovery for infectious diseases remains a high priority on the public health agenda. This issue of Drug Discovery Today: Disease Mechanisms provides state-of-the-art updates on the mechanisms by which clinically important pathogens cause disease.
With best wishes, William R. Bishai Eric Nuermberger
